Inhaled Epoprostenol for the Treatment of Pulmonary Arterial Hypertension in Critically Ill Adults

被引:31
作者
Buckley, Mitchell S. [1 ]
Feldman, Jeremy P. [2 ]
机构
[1] Banner Good Samaritan Med Ctr, Dept Pharm, Phoenix, AZ 85006 USA
[2] Arizona Pulm Specialists Ltd, Phoenix, AZ USA
来源
PHARMACOTHERAPY | 2010年 / 30卷 / 07期
关键词
epoprostenol; inhalation; pulmonary arterial hypertension; PAH; critical illness; RESPIRATORY-DISTRESS-SYNDROME; MITRAL-VALVE-REPLACEMENT; HEART-TRANSPLANT CANDIDATES; RIGHT-VENTRICULAR FUNCTION; NITRIC-OXIDE; AEROSOLIZED PROSTACYCLIN; CARDIAC TRANSPLANTATION; CARDIOPULMONARY BYPASS; NEBULIZED PROSTACYCLIN; DOSE-RESPONSE;
D O I
10.1592/phco.30.7.728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pulmonary arterial hypertension (PAH) is a progressive disease without a cure. The primary treatment goal for patients with this disease is improving pulmonary blood flow through vasodilation of the pulmonary arteries. Several drugs are available that ameliorate walk distance and hemodynamics, but their maximum tolerated doses are limited in critically ill patients with PAH because of systemic vasodilation resulting in hypotension. The ideal vasodilator would be cost-effective, safe, and selective to the pulmonary vasculature; no such agent currently exists. Inhaled nitric oxide selectively reduces pulmonary pressures without systemic hypotension. However, it is expensive, potentially toxic, and requires complex technology for monitoring and administration. Inhaled epoprostenol may be an alternative therapy to minimize systemic hypotension, which often accompanies rapid intravenous titration. To evaluate the safety and efficacy of inhaled epoprostenol in critically ill patients with PAH, we conducted a literature search by using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases (1966 August 2009) for relevant studies. Case reports and in vitro studies were excluded. Overall, 11 studies met the inclusion criteria. The PAH population included patients requiring cardiac surgery, lung or heart transplantation, or nonspecific intensive care. All trials showed that inhaled epoprostenol significantly decreased pulmonary pressures without lowering systemic blood pressure. The duration of therapy in most studies was 10-15 minutes, with one study evaluating its effects up to an average of 45.6 hours. Pulmonary pressures returned to baseline soon after drug discontinuation. Minimal adverse events were reported. Thus, inhaled epoprostenol in various subgroups of critically ill patients was effective in reducing pulmonary pressures. However, the significance of these effects on improving clinical outcomes remains unknown. Further studies are needed to determine the role of inhaled epoprostenol in critically ill patients with PAH.
引用
收藏
页码:728 / 740
页数:13
相关论文
共 50 条
[41]   Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension [J].
Reichenberger, Frank ;
Mainwood, Ann ;
Morrell, Nicholas W. ;
Parameshwar, Jayan ;
Pepke-Zaba, Joanna .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2011, 24 (01) :169-173
[42]   Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus [J].
Saiki, Chihiro ;
Kashiwado, Yusuke ;
Yokoyama, Taku ;
Ayano, Masahiro ;
Imabayashi, Keisuke ;
Kawano, Shotaro ;
Higashioka, Kazuhiko ;
Kimoto, Yasutaka ;
Fukata, Mitsuhiro ;
Mitoma, Hiroki ;
Ono, Nobuyuki ;
Arinobu, Yojiro ;
Akashi, Koichi ;
Horiuchi, Takahiko ;
Niiro, Hiroaki .
MODERN RHEUMATOLOGY CASE REPORTS, 2022, 6 (02) :183-188
[43]   Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension [J].
Satoh, Mari ;
Aso, Keiko ;
Nakayama, Tomotaka ;
Saji, Tsutomu .
ENDOCRINE JOURNAL, 2017, 64 (12) :1173-1180
[44]   Inhaled Therapies for Pulmonary Hypertension [J].
Hill, Nicholas S. ;
Preston, Ioana R. ;
Roberts, Kari E. .
RESPIRATORY CARE, 2015, 60 (06) :794-802
[45]   Acute Pulmonary Vasodilator Testing With Inhaled Treprostinil in Children With Pulmonary Arterial Hypertension [J].
Shinichi Takatsuki ;
Donna K. Parker ;
Aimee K. Doran ;
Robert H. Friesen ;
D. Dunbar Ivy .
Pediatric Cardiology, 2013, 34 :1006-1012
[46]   Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension [J].
Simonneau, Gerald ;
Rubin, Lewis J. ;
Galie, Nazzareno ;
Barst, Robyn J. ;
Fleming, Thomas R. ;
Frost, Adaani ;
Engel, Peter ;
Kramer, Mordechai R. ;
Serdarevic-Pehar, Marjana ;
Layton, Gary R. ;
Sitbon, Olivier ;
Badesch, David B. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07) :689-697
[47]   Considerations for Inotrope and Vasopressor Use in Critically III Patients With Pulmonary Arterial Hypertension [J].
Adie, Sarah K. ;
Abdul-Aziz, Ahmad A. ;
Ketcham, Scott W. ;
Moles, Victor M. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (01) :11-17
[48]   Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review [J].
Feenstra, John ;
Hopkins, Peter ;
Trotter, Michael ;
O'Brien, Kathy .
INTERNAL MEDICINE JOURNAL, 2020, 50 (11) :1377-+
[49]   Ventilation-perfusion relationships in pulmonary arterial hypertension:: Effect of intravenous and inhaled prostacyclin treatment [J].
Bratel, Tomas ;
Lagerstrand, Lars ;
Brodin, Lars-Ake ;
Nowak, Jacek ;
Randmaa, Ivar .
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2007, 158 (01) :59-69
[50]   Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertension [J].
Norman, Peter .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2015, 25 (08) :939-944